

Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- Andrew Evens named editor-in-chief of the British Journal of Haematology; Phillip Scheinberg named editor-in-chief of eJHaem
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?













